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Background/Aims: P2/MS is known as a simple, accurate, and noninvasive marker for determination of the degree of hepatic 
fibrosis in patients with viral hepatitis.  We aimed to validate P2/MS in patients with HCC. Methods: Consecutive HCC patients 
who underwent surgical resection between June 2007 and March 2009 at Seoul National University Hospital were enrolled. 
Fibrosis stage was reviewed and assessed according to METAVIR scoring. P2/MS values [platelet count (10
9/L)]
2/ [monocyte 
fraction (%)×segmented neutrophil fraction (%)] and other noninvasive fibrosis scoring systems were calculated. Results: A total 
of 171 patients were included; seven patients with METAVIR F1, 31 with F2, 41 with F3, and 92 with F4. The area under the 
receiver-operating characteristic curve of P2/MS was 0.804 [95% confidence interval (CI), 0.681~0.927] for detection of 
significant fibrosis (F2-F4) and 0.769 (95% CI, 0.698~0.839) for detection of histological cirrhosis (F4). At a value < 62, P2/MS 
detected significant fibrosis with a specificity of 85.7% (95% CI, 42.0~99.2) and a positive likelihood ratio of 4.268 (95% CI, 
0.692~26.309); and at a value > 115, P2/MS ruled out significant fibrosis with a sensitivity of 90.2% (95% CI, 84.4~94.1) and a 
negative likelihood ratio of 0.34 (95% CI, 0.106~0.095). P2/MS had a superior efficacy for detection of hepatic fibrosis in patients 
with HCC compared to the other noninvasive panels. Conclusions: P2/MS can accurately detect fibrosis in patients with HCC. 
Thus, P2/MS might be utilized as a noninvasive index reflecting the degree of hepatic fibrosis in HCC patients. (Korean J Hepatol 
2010;16:389-396)
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INTRODUCTION
Chronic hepatitis B virus (HBV) infection is the main cause of 
hepatocellular carcinoma (HCC).
1 Although it has been reported 
that up to 40% of HBV-related HCC develops in patients who do 
not have cirrhosis, almost all cases of chronic hepatitis C virus 
(HCV) related HCC occur in cirrhotic liver.
1  In most cases 
of HCC which originate from cirrhotic liver, hepatic fibrosis 
might be one of the early changes of hepatocarcinogenesis because 
cirrhotic changes of the liver could be resulted from accumulation 
and exacerbation of fibrosis.
2 On the other hand, it has been 
demonstrated that HCC patients with advanced fibrosis had 
shorter overall survival periods than those without it.
3 The 
fibrosis score is recommended for tumor-node-metastasis 
staging of HCC.
4  In addition, the Barcelona Clinic Liver 
Cancer (BCLC) classification integrated several prognostic 
factors including portal hypertension which is related to hepatic 
fibrosis.
5 Therefore, the accurate evaluation of hepatic fibrosis is 
necessary not only for determining the plan of antiviral therapy 
but also for the prognostic value in patients with HCC. The gold 390  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
standard for assessment of hepatic fibrosis has been liver biopsy.
6 
However, over- or underestimation of fibrosis can be possible 
due to intra- and interobserver variability and sampling errors.
7,8 
Several limitations, such as invasiveness, risk of complication, 
and the availability of expert practitioners, hamper the clinical 
use of liver biopsy especially when repeated tests are required.
9  
The current diagnostic strategy for HCC mostly depends on 
imaging modalities without liver biopsy.
10 Assessment modalities 
of hepatic fibrosis status without biopsy are required to help 
predict the prognosis of patients with HCC. Consequently, 
alternative noninvasive methods based on imaging studies
11,12 
and biochemical tests
13-16 have been suggested as markers of 
hepatic fibrosis. However, these tests are not able to fully replace 
liver biopsy due to the high cost or low diagnostic accuracy.
17
Recently, a simple, accurate, and noninvasive test for hepatic 
fibrosis known as P2/MS was developed.
17 It uses only simple 
laboratory tests, i.e., complete blood cell counts.
17,18 It was found 
to have high diagnostic accuracy for reflecting hepatic fibrosis 
and low cost. The favorable qualities of P2/MS were reconfirmed 
by an external validation.
16 Its clinical application for detecting 
esophageal varices was assessed by a prospective study.
19 However, 
P2/MS was developed and validated in virus-related chronic 
liver disease (CLD) patients without HCC.
17-19 The applicability 
of P2/MS in patients with HCC has not yet been validated.  In 
this study, we aimed to validate the diagnostic accuracy of 
P2/MS and compare it to those of other noninvasive fibrosis 
scoring systems in patients with HCC.
PATIENTS AND METHODS
Patients
This is a retrospective cohort study. We initially enrolled 177 
consecutive HCC patients who underwent surgical resection at 
Seoul National University Hospital, Seoul, Korea, between June 
2007 and March 2009. We excluded six patients whose surgical 
specimens were not available for evaluating the fibrosis grade of 
non-tumorous liver parenchyma. A total of 171 patients were 
included in this study. HCC was diagnosed by imaging 
modalities with/without alpha-fetoprotein levels based on the 
American Association for the Study of Liver Diseases guidelines.
10 
Tumor staging was performed in accordance with the American 
Joint Committee on Cancer (AJCC) staging system 6th edition.
4 
This study was reviewed and approved by the Institutional 
Review Board of Seoul National University Hospital.
P2/MS and Other noninvasive fibrosis scoring 
systems
Laboratory data were acquired from the included patients’ 
medical records. All noninvasive fibrosis scoring systems were 
calculated using pre-operative laboratory data. The P2/MS values 
and other noninvasive fibrosis scoring systems were calculated 
with a previously published formula as following.
17,20-23
P2/MS=[platelet count (10
9/L)]
2/[monocyte fraction (%)× 
segmented neutrophil fraction (%)]
FIB-4=[Age (years)×aspartate transaminase (AST) (U/L)]/ 
[platelet count (10
9/L)×[alanine transaminase (ALT) (U/L)]
1/2] 
Goteborg University Cirrhosis Index (GUCI)=(AST/upper 
limit of normal)×international normalization ratio (INR)×100/ 
[platelet count (10
9/L)] 
AST to platelet ratio index (APRI)=[(AST/upper limit of 
normal)/platelet count (10
9/L)]×100 
AST to ALT ratio (AAR)=AST/ALT
 
Histological examination of liver tissue
The liver surgical specimens were fixed in formalin and 
embedded in paraffin. Hematoxylin and eosin (H&E) and 
Masson’s trichrome staining were performed. Histological 
examinations were carried out by an experienced liver 
pathologist who was blinded to any clinical information. Fibrosis 
stage was reviewed and assessed in non-tumorous liver 
parenchyma according to the METAVIR scoring system.
24 
Fibrosis was staged on a scale of 0~4 as following: F0=no 
fibrosis, F1=portal fibrosis without septa, F2=few septa, 
F3=numerous septa without cirrhosis, and F4=cirrhosis. 
Significant and severe fibrosis was defined as METAVIR 
fibrosis scores of F2-F4 and F3-F4, respectively.
Statistical analysis
Spearman’s rank correlation coefficient was calculated to 
measure the correlation between P2/MS scores and the degree of 
fibrosis. Receiver operating characteristic (ROC) curves were 
constructed and the area under the ROC curve (AUROC) was 
calculated to assess the diagnostic accuracy of P2/MS. The 
AUROC of P2/MS for detecting significant fibrosis, severe 
fibrosis, and histological cirrhosis were calculated. The 
sensitivity, specificity, positive likelihood ratio (PLR), and 
negative likelihood ratio (NLR) were then calculated using the 
ROC curves at different cut-off points. All analyses were Su Jong Yu, et al. Applicability of P2/MS in patients with HCC  391
Table 1. Baseline characteristics of patients
Variables
Age (years) 56.1±10.2
Male, n (%) 132 (77.2%)
BMI (kg/m
2) 24.3±2.80
Etiology of chronic liver disease, n (%)
   Hepatitis B virus 160 (93.6%)
   Hepatitis C virus  11 (6.4%)
White cell count (/μL) 5,405.8±1,903.3
Segmented neutrophil fraction (%) 54.4±10.7
Monocyte fraction (%) 8.05±2.2
Hemoglobin (g/dL) 14.0±1.7
Platelet count (109/L) 147.1±52.9
Prothrombin time (INR) 1.1±0.1
Total bilirubin (mg/dL) 1.0±0.7
Albumin (g/dL) 4.0±0.5
AST (IU/L) 45.4±32.6
ALT (IU/L) 43.7±31.7
BUN (mg/dL) 13.9±1.7
Creatinine (mg/dL) 1.04±0.6
AJCC stage
*
   I 119 (69.6%)
   II 17 (9.9%)
   III 32 (18.7%)
   I V 3( 1 . 8 % )
Alpha-fetoprotein (ng/mL) 8,922±46,507
Fibrosis stage, n (%)
   F 0 0( 0 % )
   F 1 7( 4 . 1 % )
   F2 31 (18.1%)
   F3 41 (24.0%)
   F4 92 (53.8%)
Values are expressed as mean±SD for continuous variables.
* According to American Joint Committee on Cancer staging 
system (6th edition, 2002).
4
BMI, body mass index; INR, international normalization ratio; 
AST, aspartate transaminase; ALT, alanine transaminase; BUN, 
blood urea nitrogen.
Figure 1. Box plot of P2/MS according to the fibrosis stage by 
the METAVIR scoring system.
24 Boxes represent interquartile 
ranges, whiskers indicate highest and lowest values, circles represent
outliers, and horizontal lines within boxes indicate median 
values. P2/MS values showed a significant inverse Spearman’s
correlation according to the METAVIR fibrosis score. 
P2/MS, [platelet count (10
9/L)]
2/[monocyte fraction (%)×segmented
neutrophil fraction (%)].
conducted using SPSS version 17.0 (SPSS Inc., Chicago, IL, 
USA) and STATA version 10.0 (STATA Corp., College Station, 
TX, USA). P< 0.05 was considered significant.
RESULTS
Patient characteristics
The patient characteristics are summarized in Table 1. One 
hundred thirty two (77.2%) patients were male, and the mean age 
was 56.1±10.2 years. One hundred thirty six (79.5%) patients 
belonged to AJCC stage I and II. Fibrosis stage was determined 
in all 171 patients: seven patients with METAVIR F1, 31 with F2, 
41 with F3, and 92 with F4.  Scores for P2/MS ranged from 0.51 
to 196.48.
Diagnostic accuracy of P2/MS
The mean values decreased as a function of the fibrosis score, 
ranging from 104.97±46.87 for F1 cases to 44.20±33.30 for F4 
cases. P2/MS scores showed a significant inverse Spearman’s 
correlation with the METAVIR fibrosis score (Fig. 1; Spearman’s 
correlation coefficient = -0.481, P<0.001). However, P2/MS 
scores didn’t show a significant Spearman’s correlation with 
TNM stage (Spearman’s correlation coefficient = -0.020, 
P=0.799).
Regarding the fibrosis grade, the AUROC was 0.804 [95% 
confidence interval (CI), 0.681~0.927; P=0.007] for detecting 
significant fibrosis (F2-F4), 0.749 (95% CI, 0.669~0.829; 
P<0.001) for detecting severe fibrosis (F3-F4), and 0.769 (95% 
CI, 0.698-0.839; P<0.001) for detecting histological cirrhosis 
(F4) (Fig. 2). The sensitivity, specificity, PLR, and NLR of 
P2/MS were calculated using previously published cut-off values 
(Table 2).
17,18 At a cut-off value <62, P2/MS detected significant 
fibrosis with a specificity of 85.7% (95% CI, 42.0~99.2) and a 
PLR of 4.27 (95% CI, 0.69~26.31); and at a cut-off value>115, 
P2/MS ruled out significant fibrosis with a sensitivity of 90.2% 
(95% CI, 84.4~94.1) and a NLR of 0.34 (95% CI, 0.11~1.10).  At 
a cut-off value <30, P2/MS detected histological cirrhosis with a 392  The Korean Journal of Hepatology Vol. 16. No. 4, December 2010
   
Figure 2. ROC curves of P2/MS for detection of fibrosis. P2/MS showed significant diagnostic accuracy for detection of fibrosis. The 
AUROC was 0.804 (P=0.007) for detection of significant fibrosis (F2-F4) (A), 0.749 (P<0.001) for detection of severe fibrosis (F3-F4) 
(B), and 0.769 (P<0.001) for detection of histological cirrhosis (F4) (C). 
ROC, receiver-operating characteristic; P2/MS, [platelet count (10
9/L)]
2/[monocyte fraction (%)×segmented neutrophil fraction (%)]; 
AUROC, area under the receiver operating characteristic curve.
Table 2. Predictive values of P2/MS for diagnosis of significant fibrosis and histological cirrhosis
Cut-off Sensitivity (%) Specificity (%) PLR (95% CI) NLR (95% CI) Interpretation
Significant 
fibrosis
<62 61.0
(53.0~68.4)
85.7
(42.0~99.2)
4.27
(0.69~26.30)
0.46
(0.36~0.58)
Significant fibrosis
>115 90.2
(84.4~94.1)
28.6
(5.1~69.7)
1.26
(0.79~2.02)
0.34
(0.11~1.10)
No significant fibrosis
Histological 
cirrhosis
<30 40.2
(30.3~51.0)
92.4
(83.6~96.9)
5.30
(2.36~11.89)
0.65
(0.55~0.77)
Histological cirrhosis
>83 89.1
(80.5~94.4)
41.8
(30.9~53.4)
1.53
(1.25~1.87)
0.26
(0.14~0.48)
No histological cirrhosis
CI, confidence interval; PLR, positive likelihood ratio; NLR, negative likelihood ratio.
Table 3. Values of noninvasive fibrosis scoring systems
F0-F1 (n=7) F2-F4 (n=164) P-value
*
P2/MS mean±SD 104.98±46.87 58.11±38.34 0.007
median (range) 92.64 (49.44~196.48) 51.57 (0.51~174.35)
FIB-4 mean±SD 2.76±1.61 3.50±3.55 0.785
median (range) 2.28 (1.12~5.70) 2.38 (0.65~25.73)
GUCI mean±SD 1.13±1.51 1.08±1.07 0.454
median (range) 0.59 (0.27~4.52) 0.73 (0.16~6.46)
APRI mean±SD 1.03±1.34 0.95±0.88 0.523
median (range) 0.52 (0.26~4.03) 0.64 (0.16~5.52)
AAR mean±SD 1.33±0.37 1.17±0.62 0.107
median (range) 1.33 (0.74~1.84) 1.00 (0.50~4.07)
* Compared by Mann-Whitney U tests.
P2/MS, [platelet count (10
9/L)]
2/[monocyte fraction (%)×segmented neutrophil fraction (%)]; GUCI, Goteborg University Cirrhosis 
Index; APRI, AST to platelet ratio index; AAR, AST to ALT ratio.
specificity of 92.4% (95% CI, 83.6~96.9) and a PLR of 5.30 
(95% CI, 2.36~11.89); and at a cut-off value > 83, P2/MS ruled 
out histological cirrhosis with a sensitivity of 89.1% (95% CI, 
80.5~94.4) and a NLR of 0.26 (95% CI, 0.14~0.48).
To avoid the confounding effects of the initial tumor stage and 
the etiology of HCC, we evaluated the diagnostic accuracy of 
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Table 4. AUROC of noninvasive fibrosis scoring systems for prediction of significant fibrosis
Noninvasive fibrosis scoring systems AUROC (95% CI) P-value
*
P2/MS 0.804 (0.681~0.927) -
FIB-4 0.530 (0.328~0.733)  0.031
GUCI 0.584 (0.358~0.810)  0.072
APRI 0.571 (0.339~0.804)  0.060
AAR 0.320 (0.137~0.502) <0.001
* Compared to AUROC of P2/MS.
AUROC, area under the receiver operating characteristic curve; CI, confidence interval; P2/MS, [platelet count (10
9/L)]
2/[monocyte 
fraction (%)×segmented neutrophil fraction (%)]; GUCI, Goteborg University Cirrhosis Index; APRI, AST to platelet ratio index; 
AAR, AST to ALT ratio.
Figure 3. Comparison of ROC of P2/MS and other noninvasive fibrosis scoring systems for diagnosis of significant fibrosis (F2-F4) 
(A) and histological cirrhosis (F4) (B). For detection of significant fibrosis (F2-F4) and histological cirrhosis (F4), the AUROC was 
the greatest for P2/MS. 
P2/MS, [platelet count (10
9/L)]
2/[monocyte fraction (%)×segmented neutrophil fraction (%)]; GUCI, Goteborg University Cirrhosis 
Index; APRI, AST to platelet ratio index; AAR, AST to ALT ratio; ROC, receiver-operating characteristic; AUROC, area under the 
receiver operating characteristic curve.
Table 5. AUROC of noninvasive fibrosis scoring systems for prediction of histological cirrhosis
Noninvasive fibrosis scoring systems AUROC (95% CI) P-value
*
P2/MS 0.769 (0.698~0.839) -
FIB-4 0.704 (0.627~0.782)  0.221
GUCI 0.717 (0.639~0.795)  0.323
APRI 0.701 (0.622~0.780)  0.201
AAR 0.536 (0.449~0.623) <0.001
* Compared to AUROC of P2/MS
AUROC, area under the receiver operating characteristic curve; CI, confidence interval; P2/MS, [platelet count (10
9/L)]
2/[monocyte 
fraction (%)×segmented neutrophil fraction (%)]; GUCI, Goteborg University Cirrhosis Index; APRI, AST to platelet ratio index; 
AAR, AST to ALT ratio.
P2/MS according to HCC stage and the etiology of HCC, which 
could affect the hematologic data or hepatic fibrosis status. For 
119 (69.6%) patients of AJCC stage I, the AUROC of P2/MS 
was 0.821 (95% CI, 0.731~0.910; P=0.121) for detecting significant 
fibrosis (F2-F4), 0.724 (95% CI, 0.617~0.832; P=0.001) for 
detecting severe fibrosis (F3-F4), and 0.721 (95% CI, 0.630~0.812; 
P<0.001) for detecting histological cirrhosis (F4). Within HBV- 
related HCC [160 (93.6%) of all patients], the AUROC of P2/MS 
was 0.821 (95% CI, 0.7230.918; P=0.029) for detecting significant 
fibrosis (F2-F4), 0.731 (95% CI, 0.645~0.817; P<0.001) for detecting 
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severe fibrosis (F3-F4), and 0.766 (95% CI, 0.692~0.839; P<0.001) 
for detecting histological cirrhosis (F4).
Comparison of P2/MS and other noninvasive 
fibrosis scoring systems
Mean values of noninvasive fibrosis scoring systems were 
summarized in Table 3. To evaluate the diagnostic value of 
noninvasive fibrosis scoring systems for significant fibrosis, we 
compared the AUROC of P2/MS with those of other tests 
(Table 4). The AUROC was greatest for P2/MS (0.804; 95% CI, 
0.681~0.927), then GUCI (0.584; 95% CI, 0.358~0.810) followed 
by APRI (0.571; 95% CI, 0.339~0.804), FIB-4 (0.530; 95% CI, 
0.328~0,733), and AAR (0.320; 95% CI, 0.137~0.502). Furthermore, 
there was a significant difference between the AUROC for 
P2/MS and the AUROCs for FIB-4 and AAR. The AUROC of 
P2/MS showed a tendency to increase compared to those of 
GUCI and APRI (Fig. 3A). For histological cirrhosis, although 
there were no statistically significant differences between the 
AUROC for P2/MS and the AUROCs for other noninvasive 
fibrosis scoring systems except AAR, the AUROC was greatest 
for P2/MS (0.769; 95% CI, 0.698~0.839), then GUCI (0.717; 
95% CI, 0.639~0.795) followed by FIB-4 (0.704; 95% CI, 
0.627~0.782), APRI (0.701; 95% CI, 0.622~0.780), and AAR 
(0.536; 95% CI, 0.449~0.623) (Fig. 3B, Table 5).
DISCUSSION
The principal findings of this study relate to the detection of 
significant hepatic fibrosis of patients with HCC by P2/MS. 
P2/MS showed an inverse Spearman’s correlation with the 
METAVIR score of patients with HCC and statistically significant 
diagnostic accuracy for detecting significant fibrosis (METAVIR 
F2-F4), severe fibrosis (METAVIR F3-F4), and histological 
cirrhosis (METAVIR F4). Furthermore, among noninvasive 
fibrosis scoring systems, only P2/MS showed superior diagnostic 
accuracy to other noninvasive fibrosis scoring systems for 
detecting significant fibrosis (METAVIR F2-F4) in this study. 
For histological cirrhosis (METAVIR F4), the diagnostic accuracy 
was greatest for P2/MS among noninvasive fibrosis scoring 
systems and there was a statistically significant difference between 
that of P2/MS and AAR.
The early detection of hepatic fibrosis is important for 
predicting clinical outcomes of patients with HCC.
4 In addition, 
hepatic fibrosis is a determinant factor for the antiviral therapy 
strategy in patients with HBV replication and raised ALT levels, 
or those with high normal ALT levels and who are older than 40 
years.
25 However, the current gold standard for the diagnosis of 
hepatic fibrosis is a liver biopsy which has several disadvantages, 
such as poor compliance, invasiveness, complications, and cost.
9 
Therefore, noninvasive modalities of evaluating hepatic fibrosis 
have been proposed to overcome these problems. The two 
principal categories of noninvasive tests include serum fibrosis 
panels and hepatic elasticity imaging.
23 However, these modalities 
have not showed sufficient diagnostic efficacy for complete 
replacement of liver biopsy.
18 In the meantime, P2/MS, a new, 
accurate method, based only on a complete blood cell count, was 
developed for reflecting significant fibrosis (METAVIR F2-F4) 
and cirrhosis (METAVIR F4) in virus-related CLD.
17 Moreover, 
this was reconfirmed recently by two external comprehensive 
and prospective validation studies.
18,19  However, a validation 
study is necessary before applying P2/MS to patients with HCC 
and our study is the first investigation to examine the diagnostic 
value of P2/MS in patients with HCC.
In this study, P2/MS detected significant fibrosis (METAVIR 
F2-F4) at a cut-off value <62 and effectively ruled out significant 
fibrosis (METAVIR F2-F4) at a cut-off value >115. This was 
consistent with the result of a P2/MS study by Lee et al.
17 
However, for the detection of histological cirrhosis, P2/MS 
detected histological cirrhosis at a cut-off value <30, and effectively 
ruled out histological cirrhosis at a cut-off value > 83. This was not 
consistent with a P2/MS study by Lee et al,
17 but was con-
sistent with the cut-off values proposed by Kim et al.
18 Among 
our study population, chronic hepatitis B (CHB) patients were 
93.6% and chronic hepatitis C (CHC) patients are only 6.4%. 
The study population of the external validation study by Kim et 
al
18 consisted entirely of all CHB patients. In contrast, in P2/MS 
study by Lee et al,
17 46 (22.4%) of 205 patients in the derivation 
set were CHC patients. The composition of our study pop-
ulation was more similar to the external validation study by 
Kim et al.
18 and for the detection of histological cirrhosis in pa-
tients with HCC, cut-off values proposed by Kim et al
18 seem 
to be acceptable.
The AUROC of FIB-4 and GUCI were 0.704 and 0.717 for 
diagnosis of histological cirrhosis in our study, respectively. 
These are somewhat inferior to previous reports for the 
FIB-4 and GUCI where AUROCs of 0.91 and 0.85 have been 
reported.
20,21 The discrepancies seem to originate from the 
difference in study populations between our study and previous 
studies. CHB patients were dominant and a few CHC patients 
were enrolled in our study. In contrast, study populations of Su Jong Yu, et al. Applicability of P2/MS in patients with HCC  395
previous studies were composed of hepatitis C virus-infected 
patients only. Recently, it has been suggested that the pathogenesis 
of liver fibrosis in CHB is different from that of CHC,
26 in which 
the hepatic necroinflammatory activity of CHB is decreased after 
recurrent hepatitis B flares and HBeAg seroconversion is 
observed after the development of cirrhosis.
27 In contrast, 
CHC is a progressive disease with persistent inflammation that is 
related to liver cirrhosis.
27  Consequently, CHB has specific 
mechanisms for liver fibrosis and cirrhosis different from those 
of CHC.
27 Moreover, patients with space-occupying lesions 
such as HCC might have higher transaminase levels.
27 In 
addition, the fluctuating patterns of transaminase activity in 
patients with chronic viral hepatitis may be an important 
limitation for the use of noninvasive fibrosis scoring systems 
containing AST or ALT.
28
The diagnostic accuracy of P2/MS was not increased when 
analyzed according to tumor stage or the etiology of HCC. That 
might be related with small case numbers of our study and it 
made our study prone to type II errors.
29  Thus, prospective 
studies with large number of patients are warranted to evaluate 
the effect of tumor stage or the etiology of HCC on the diagnostic 
accuracy of P2/MS.
The AUROC of P2/MS for significant fibrosis (METAVIR 
F2-F4) and histological cirrhosis (METAVIR F4) were 0.804 
and 0.769 in our study, respectively. These relatively lower 
diagnostic yields compared to the previous studies excluding 
HCC patients may be related to smaller changes in the platelet 
count along with monocyte and segmented neutrophil fractions 
in mild liver fibrosis than in cirrhosis as discussed before.
17 
Although the platelet count was thought to be a significant 
predictor of liver fibrosis in patients with CLD, platelet counts 
could significantly vary over time among patients with CLD.
27 
Most of the patients with HCC had severe fibrosis (METAVIR 
F3-F4) or histological cirrhosis (METAVIR F4), and thereafter 
the paucity of normal to mild liver fibrosis for comparison was a 
limitation. Although the performance of P2/MS for detecting 
significant fibrosis (METAVIR F2-F4) in patients with HCC 
was not satisfactory, this index had greatest efficacy among 
noninvasive fibrosis scoring systems. However, since our study 
was a retrospective analysis performed in a single medical 
center, an independent external validation of P2/MS in patients 
with HCC by prospective studies is required. Moreover, compared 
to previous study about APRI or AAR, the case numbers are too 
small, so further prospective studies are warranted for precise 
comparison among well known noninvasive fibrosis scoring 
systems.
In conclusion, P2/MS showed significant diagnostic accuracy 
for the detection of significant fibrosis (METAVIR F2-F4), 
severe fibrosis (METAVIR F3-F4), and histological cirrhosis 
(METAVIR F4) in patients with HCC. Furthermore, P2/MS 
showed the greatest diagnostic accuracy among noninvasive 
fibrosis scoring systems in patients with HCC. These findings 
indicate that P2/MS, which is only based on complete blood cell 
count and differential cell count results, maintained diagnostic 
accuracy in patients with HCC.  Therefore, P2/MS can be utilized 
as a noninvasive fibrosis scoring systems reflecting the degree of 
hepatic fibrosis in patients with HCC as well as ones with viral 
hepatitis, but without HCC.
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